Cost-effectiveness of vaccination against herpes zoster

References

• Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365 - 76; http://dx.doi.org/10.1016/S0140-6736(06)69561-5; PMID: 17046469
   PubMed Web of Science ®Google Scholar
• Hope-Simpson RE. The nature of herpes zoster: A long-term study and a new hypothesis. Proc R Soc Med 1965; 58:9 - 20; PMID: 14267505
   PubMedGoogle Scholar
• Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007; 11:Suppl 2 S43 - 8; http://dx.doi.org/10.1016/S1201-9712(07)60021-6; PMID: 18162246
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010; 182:1731 - 6; http://dx.doi.org/10.1503/cmaj.091711; PMID: 20921251
   PubMed Web of Science ®Google Scholar
• Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000; 321:794 - 6; http://dx.doi.org/10.1136/bmj.321.7264.794; PMID: 11009518
   PubMed Web of Science ®Google Scholar
• Wareham DW, Breuer J. Herpes zoster. BMJ 2007; 334:1211 - 5; http://dx.doi.org/10.1136/bmj.39206.571042.AE; PMID: 17556477
   PubMed Web of Science ®Google Scholar
• Opstelten W, Van Essen GA, Schellevis F, Verheij TJM, Moons KGM. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006; 16:692 - 5; http://dx.doi.org/10.1016/j.annepidem.2005.12.002; PMID: 16516488
   PubMed Web of Science ®Google Scholar
• Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996; 9:361 - 81; PMID: 8809466
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Portenoy RK. Proposed classification of herpes zoster pain. Lancet 1994; 343:1648 - 1648; http://dx.doi.org/10.1016/S0140-6736(94)93106-2; PMID: 7911959
   PubMed Web of Science ®Google Scholar
• Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ, Verheij TJ, Moons KG. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007; 132:Suppl 1 S52 - 9; http://dx.doi.org/10.1016/j.pain.2007.02.004; PMID: 17379412
   PubMedGoogle Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18:350 - 4; http://dx.doi.org/10.1097/00002508-200211000-00002; PMID: 12441828
   PubMed Web of Science ®Google Scholar
• Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, Breuer J. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70:Suppl 1 S24 - 30; http://dx.doi.org/10.1002/jmv.10316; PMID: 12627483
   PubMedGoogle Scholar
• Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25:571 - 5; PMID: 1195231
   PubMedGoogle Scholar
• Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6:356 - 63; http://dx.doi.org/10.1016/j.jpain.2005.01.359; PMID: 15943957
   PubMed Web of Science ®Google Scholar
• Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: State of the evidence. Hum Vaccin Immunother 2013; •••:9; PMID: 23570049
   PubMed Web of Science ®Google Scholar
• Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23:490 - 6; http://dx.doi.org/10.1097/AJP.0b013e318065b6c9; PMID: 17575488
   PubMed Web of Science ®Google Scholar
• Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39:342 - 8; http://dx.doi.org/10.1086/421942; PMID: 15307000
   PubMed Web of Science ®Google Scholar
• Mitka M. FDA approves shingles vaccine: herpes zoster vaccine targets older adults. JAMA 2006; 296:157 - 8; http://dx.doi.org/10.1001/jama.296.2.157; PMID: 16835412
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Zostavax: EPAR - product information. 2013; 2013.
   Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al, Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271 - 84; http://dx.doi.org/10.1056/NEJMoa051016; PMID: 15930418
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008; 197:Suppl 2 S228 - 36; http://dx.doi.org/10.1086/522159; PMID: 18419402
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr., McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922 - 8; http://dx.doi.org/10.1093/cid/cir970; PMID: 22291101
   PubMed Web of Science ®Google Scholar
• Baxter R, Tran TN, Hansen J, Emery M, Fireman B, Bartlett J, Lewis N, Saddier P. Safety of Zostavax™--a cohort study in a managed care organization. Vaccine 2012; 30:6636 - 41; http://dx.doi.org/10.1016/j.vaccine.2012.08.070; PMID: 22963800
   PubMed Web of Science ®Google Scholar
• Vesikari T, Hardt R, Rumke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (zostavax ((R))) in individuals aged >/= 70 years: A randomized study of a single dose versus two different two-dose schedules. Hum Vaccin Immunother 2013; •••:9; PMID: 23570049
   PubMed Web of Science ®Google Scholar
• Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, Levin MJ, Schmader KE, Gelb LD, Keay S, et al, Shingles Prevention Study Group. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010; 152:545 - 54; http://dx.doi.org/10.7326/0003-4819-152-9-201005040-00004; PMID: 20439572
   PubMed Web of Science ®Google Scholar
• Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S, Baxter R, Nordin J, et al, Vaccine Safety Datalink (VSD) Team. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med 2012; 271:510 - 20; http://dx.doi.org/10.1111/j.1365-2796.2011.02474.x; PMID: 22026504
   PubMed Web of Science ®Google Scholar
• Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al, Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320 - 8; http://dx.doi.org/10.1093/cid/cis638; PMID: 22828595
   PubMed Web of Science ®Google Scholar
• Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137:38 - 47; http://dx.doi.org/10.1017/S0950268808000678; PMID: 18466661
   PubMed Web of Science ®Google Scholar
• Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007; 25:155 - 69; http://dx.doi.org/10.2165/00019053-200725020-00007; PMID: 17249857
   PubMed Web of Science ®Google Scholar
• Wasem J, Lang K, Papageorgiou M, Ultsch B, Martin M. Health economic evaluation of a new vaccine for the prevention of herpes zoster and post-herpetic neuralgia in adults a german analysis. Value Health 2009; 12:A294; http://dx.doi.org/10.1016/S1098-3015(10)74442-9
   Web of Science ®Google Scholar
• Ultsch B, Reinhold T, Siedler A, Krause G, Wichmann O. Health economic evaluation of the vaccination against herpes zoster and postherpetic neuralgia in germany. Value Health 2012; 15:A394; http://dx.doi.org/10.1016/j.jval.2012.08.1118
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Melegaro A, Gay N, Bilcke J, Edmunds WJ. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine 2012; 30:1225 - 34; http://dx.doi.org/10.1016/j.vaccine.2011.11.026; PMID: 22119592
   PubMed Web of Science ®Google Scholar
• Bilcke J, Jan van Hoek A, Beutels P. Childhood varicella-zoster virus vaccination in belgium: Cost-effective only in the long run or without exogenous boosting?. Hum Vaccin Immunother 2013; •••:9; PMID: 23570049
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19:3076 - 90; http://dx.doi.org/10.1016/S0264-410X(01)00044-5; PMID: 11312002
   PubMed Web of Science ®Google Scholar
• Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145:317 - 25; http://dx.doi.org/10.7326/0003-4819-145-5-200609050-00004; PMID: 16954357
   PubMed Web of Science ®Google Scholar
• Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25:8326 - 37; http://dx.doi.org/10.1016/j.vaccine.2007.09.066; PMID: 17980938
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44:1280 - 8; http://dx.doi.org/10.1086/514342; PMID: 17443464
   PubMed Web of Science ®Google Scholar
• Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008; 4:238 - 45; http://dx.doi.org/10.4161/hv.4.3.5686; PMID: 18382137
   PubMed Web of Science ®Google Scholar
• Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009; 27:991 - 1004; http://dx.doi.org/10.2165/11314010-000000000-00000; PMID: 19908924
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27:1454 - 67; http://dx.doi.org/10.1016/j.vaccine.2008.12.024; PMID: 19135492
   PubMed Web of Science ®Google Scholar
• Annemans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ 2010; 13:537 - 51; http://dx.doi.org/10.3111/13696998.2010.502854; PMID: 20707768
   PubMedGoogle Scholar
• Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc 2010; 8:7-7547-8-7.
   Google Scholar
• van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the netherlands. BMC Health Serv Res 2010; 10:237-6963-10-237.
   Google Scholar
• Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin 2011; 7:749 - 56; http://dx.doi.org/10.4161/hv.7.7.15573; PMID: 21606685
   PubMed Web of Science ®Google Scholar
• Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine 2012; 30:675 - 84; http://dx.doi.org/10.1016/j.vaccine.2011.10.036; PMID: 22120193
   PubMed Web of Science ®Google Scholar
• Bresse X, Annemans L, Preaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in france: A cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2013.
   Google Scholar
• de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine 2013; 31:1276 - 83; http://dx.doi.org/10.1016/j.vaccine.2012.12.067; PMID: 23306360
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York: Oxford University Press Inc.; 2005.
   Google Scholar
• Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics 2013; 31:125 - 36; http://dx.doi.org/10.1007/s40273-012-0020-7; PMID: 23335045
   PubMed Web of Science ®Google Scholar
• Drummond MF, Jefferson TO, The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313:275 - 83; http://dx.doi.org/10.1136/bmj.313.7052.275; PMID: 8704542
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, Chiou CF, Henning JM, Wade SW, Hay JW. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003; 9:53 - 61; PMID: 14613362
   PubMedGoogle Scholar
• Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5:344 - 56; http://dx.doi.org/10.1016/j.jpain.2004.06.001; PMID: 15336639
   PubMed Web of Science ®Google Scholar
• Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33:337 - 43; http://dx.doi.org/10.3109/07853890109002087; PMID: 11491192
   PubMed Web of Science ®Google Scholar
• Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?. Vaccine 2012; 30:2795 - 800; http://dx.doi.org/10.1016/j.vaccine.2011.09.079; PMID: 21964056
   PubMed Web of Science ®Google Scholar
• Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis 2007; 45:1527 - 9; http://dx.doi.org/10.1086/523011; PMID: 17990240
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC vaccine price list. March 7 2013; 2013.
   Google Scholar
• Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, Seward JF. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005; 5:68; http://dx.doi.org/10.1186/1471-2458-5-68; PMID: 15960856
   PubMed Web of Science ®Google Scholar
• Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002 - 7; http://dx.doi.org/10.1086/430325; PMID: 15897984
   PubMed Web of Science ®Google Scholar
• Grant KA, Carville KS, Kelly HA. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med J Aust 2010; 193:483; PMID: 20955129
   PubMed Web of Science ®Google Scholar
• Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011; 52:332 - 40; http://dx.doi.org/10.1093/cid/ciq077; PMID: 21217180
   PubMed Web of Science ®Google Scholar
• Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 2011; 29:8580 - 4; http://dx.doi.org/10.1016/j.vaccine.2011.09.024; PMID: 21939721
   PubMed Web of Science ®Google Scholar
• Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008. Epidemiol Infect 2012; 140:1131 - 40; http://dx.doi.org/10.1017/S0950268811001786; PMID: 21906410
   PubMed Web of Science ®Google Scholar
• Goldman GS, King PG. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine 2013; 31:1680 - 94; http://dx.doi.org/10.1016/j.vaccine.2012.05.050; PMID: 22659447
   PubMed Web of Science ®Google Scholar
• Ogunjimi B, Van Damme P, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: A systematic multidisciplinary review. PLoS One 2013; 8:e66485; http://dx.doi.org/10.1371/journal.pone.0066485; PMID: 23805224
   PubMed Web of Science ®Google Scholar
• Hethcote H. The mathematics of infectious diseases. SIAM Rev 2000; 42:599 - 653; http://dx.doi.org/10.1137/S0036144500371907
   Web of Science ®Google Scholar
• Pinchinat S, Cebrian-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across europe: Results from a systematic literature review. BMC Infect Dis 2013; 13:170-2334-13-170..
   Google Scholar